Assessing the Sustainability of Liquid Hydrogen for Future Hypersonic Aerospace Flight

This is the final version. Available on open access from MDPI via the DOI in this recordThis study explored the applications of liquid hydrogen (LH2) in aerospace projects, followed by an investigation into the efficiency of ramjets, scramjets, and turbojets for hypersonic flight and the impact of grey, blue, and green hydrogen as an alternative to JP-7 and JP-8 (kerosene fuel). The advantage of LH2 as a propellant in the space sector has emerged from the relatively high energy density of hydrogen per unit volume, enabling it to store more energy compared to conventional fuels. Hydrogen also has the potential to decarbonise space flight as combustion of LH2 fuel produces zero carbon emissions. However, hydrogen is commonly found in hydrocarbons and water and thus it needs to be extracted from these molecular compounds before use. Only by considering the entire lifecycle of LH2 including the production phase can its sustainability be understood. The results of this study compared the predicted Life Cycle Assessment (LCA) emissions of the production of LH2 using grey, blue, and green hydrogen for 2030 with conventional fuel (JP-7 and JP-8) and revealed that the total carbon emissions over the lifecycle of LH2 were greater than kerosene-derived fuels

Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection

The potential for ischemic preconditioning to reduce infarct size was first recognized more than 30 years ago. Despite extension of the concept to ischemic postconditioning and remote ischemic conditioning and literally thousands of experimental studies in various species and models which identified a multitude of signaling steps, so far there is only a single and very recent study, which has unequivocally translated cardioprotection to improved clinical outcome as the primary endpoint in patients. Many potential reasons for this disappointing lack of clinical translation of cardioprotection have been proposed, including lack of rigor and reproducibility in preclinical studies, and poor design and conduct of clinical trials. There is, however, universal agreement that robust preclinical data are a mandatory prerequisite to initiate a meaningful clinical trial. In this context, it is disconcerting that the CAESAR consortium (Consortium for preclinicAl assESsment of cARdioprotective therapies) in a highly standardized multi-center approach of preclinical studies identified only ischemic preconditioning, but not nitrite or sildenafil, when given as adjunct to reperfusion, to reduce infarct size. However, ischemic preconditioning—due to its very nature—can only be used in elective interventions, and not in acute myocardial infarction. Therefore, better strategies to identify robust and reproducible strategies of cardioprotection, which can subsequently be tested in clinical trials must be developed. We refer to the recent guidelines for experimental models of myocardial ischemia and infarction, and aim to provide now practical guidelines to ensure rigor and reproducibility in preclinical and clinical studies on cardioprotection. In line with the above guideline, we define rigor as standardized state-of-the-art design, conduct and reporting of a study, which is then a prerequisite for reproducibility, i.e. replication of results by another laboratory when performing exactly the same experiment